Exploratory Outcome Study of Ibogaine-Assisted Therapy in 20 Chemically-Dependent Persons Valerie Mojeiko Multidisciplinary Association for Psychedelic Studies (MAPS)

Ibogaine Outcome Study, V. Mojeiko1 Tabernanthe Iboga

Ibogaine Outcome Study, V. Mojeiko2

3

4 Howard Lotsof

Ibogaine Outcome Study, V. Mojeiko5 Subjective Effects Psychedelic that produces a dreamlike state Review of memories Experience lasts several days Many find it unpleasant, not a recreational drug Some experience psychological material related to addiction Greatly reduces physical and psychological withdrawal symptoms from heroin, methadone, other drugs

Ibogaine Outcome Study, V. Mojeiko6 Neurotransmitter Activities Novel mechanism of action Complex interactions between multiple neurotransmitter systems Mu-opiod agonist; NMDA antagonist; kappa opioid agonist; serotonin 5ht2a agonist; serotonin uptake inhibitor; 5ht3 agonist; dopamine uptake inhibitor; sigma opioid receptor agonist…

Ibogaine Outcome Study, V. Mojeiko7 Where do addicts take ibogaine?

Ibogaine Outcome Study, V. Mojeiko8 Hotel Rooms

Ibogaine Outcome Study, V. Mojeiko9 At Home

Ibogaine Outcome Study, V. Mojeiko10 Iboga Therapy House, Canada

Ibogaine Outcome Study, V. Mojeiko11

Ibogaine Outcome Study, V. Mojeiko12 Existing treatment facilities providing detoxification--not collecting information… How well does it work? How safe is it? What percentage of people benefit and to what degree? How can these treatments be improved? Should formal studies be conducted? MAPS’ Role: Evaluating program, providing feedback, and collecting data for research

Ibogaine Outcome Study, V. Mojeiko13 Preliminary Data: June 2004: Iboga Therapy House: 2wks-1yr after tx (avg. 6 months) 20 subjects 6 of 7 treated for Cocaine/Crack abstinent (86%) 3 of 8 treated for opiates abstinent (38%) 4/5 treated for other substances abstinent (80%)

Ibogaine Outcome Study, V. Mojeiko14 Exploratory Outcome Study Seeking to obtain basic preliminary data Not a controlled study, but is representative since including 20 Subjects treated consecutively One-year series of questionnaires and interviews from 20 subjects verified by interview with significant others Harm reduction model: looking at abstinence as well as non-abstinence outcomes, trying to differentiate between abuse and controlled use

Ibogaine Outcome Study, V. Mojeiko15 ASI-Addiction Severity Index Semi-structured 1 hour interview Scores on 7 subscales: medical status, employment and support, drug use, alcohol use, legal status, family/social status, and psychiatric status Been used extensively on a wide variety of outcome studies

Ibogaine Outcome Study, V. Mojeiko16 Peak Experience Profile (PEP) Measures the psychedelic experience 180 items; one composite score; 16 subscores Scores for peaks (highs) and nadirs (lows)

Ibogaine Outcome Study, V. Mojeiko17 Measures Addiction Severity Index (primary variable) Peak Experience Profile Beck Depression and Anxiety Inventories Subjective and Objective Opiate Withdrawal Scales (SOWS/OOWS) Pain and Craving Scales

Ibogaine Outcome Study, V. Mojeiko18 Process All interviews are conducted by evaluation coordinator Baseline in person; follow-up by phone Each interview takes about an hour or two Valerie organizes and analyzes data

Ibogaine Outcome Study, V. Mojeiko19 iPW2W ASI XXXXXXXXXXXXX BDI/BAI XXXXXXXXXXXXXX PEP X O/SOWS XXX Pain/Cra XXXXXXXXXXXXXXX SO check XXXXXXXXXXXXXXX Schedule for Outcome Measures i=Intake; P=Post-treatment; W2=Week 2; 1-12=Months 1-12

Ibogaine Outcome Study, V. Mojeiko20 Challenges No drug testing Difficulty of remaining in contact during follow-up Check-in with significant other addresses these concerns

Ibogaine Outcome Study, V. Mojeiko21 Progress End of protocol design and training phase Began study at Ibogaine Association; ended prematurely Assisting Iboga Therapy House in obtaining grant from Health Canada Partial funding obtained from private donors for study, Iboga Therapy House seeking additional funding for operating costs

Ibogaine Outcome Study, V. Mojeiko22 Goals Obtain basic information about outcomes in underground clinics Provide feedback to improve services; help win funding from Canadian government; increase safety Ideally lead to placebo-controlled double-blind studies Ibogaine available to drug addicts in a safe, supportive, and humane setting